Abstract: To report the safety and efficacy of anti-tumor necrosis factor a (TNFa) therapy in severe and refractory neuro-Behcet disease (NBD) patients.
INTRODUCTION

B
ehcet disease (BD) is a chronic and relapsing vasculitis, including recurrent oral aphthous ulcers, along with genital ulcerations, skin lesions, and uveitis. Patients may also present with arthralgia, venous and arterial thrombosis, and neurological involvement. BD affects mainly young patients, with a peculiar geographic distribution (Mediterranean and Eastern countries). Neurologic involvement occurs in 5.3% to 59% of patients. [1] [2] [3] These lesions are typically described as ''parenchymal'' and ''extraparenchymal.'' Although the clinical and imaging features of neurological involvement of BD have been extensively described, few studies have reported on the longterm outcome and treatment of neuro-BD (NBD). The treatment of parenchymal lesions of NBD is based on high doses of corticosteroids and immunosuppressants such as cyclophosphamide and azathioprine. 4 We have recently shown that cyclophosphamide tended to be more efficient than azathioprine in severe NBD patients. 5 Neurological involvement is 1 of the main cause of disability in BD. Up to 25% of our patients with neuro-BD had moderate-to-severe disabling sequelae (persistent Rankin score 3) or died after a median follow-up of 73 months. 5 There is an unmet need for less toxic and more effective immunosuppressive treatments in the management of severe and/or refractory neuro-BD patients. Many studies have shown the rapidity of action and the effectiveness of anti-tumor necrosis factor a (TNFa) in severe uveitis of BD. 6, 7 However, only case reports and compiled data from literature reviews are available for NBD and these have shown very encouraging results with the use of anti-TNFa. [8] [9] [10] The aim of the present multicenter observational study was to analyze the safety and efficacy of anti-TNFa therapy in 17 severe and refractory neurological BD patients with parenchymal involvement.
METHODS
We conducted a multicenter observational study, including 17 patients followed in 6 internal medicine, and rheumatology referral centers between 2001 and 2015. All patients with symptomatic and refractory NBD were treated with anti-TNFa antibodies, followed in the participating centers were enrolled. All patients fulfilled the international criteria for BD. 11 The study was approved by the local ethics committee. The diagnosis of NBD was based on objective neurological symptoms not explained by any other known disease or therapy associated with neuroimaging findings suggestive of BD-related central nervous system (CNS) involvement 12 and sometimes with cerebrospinal fluid (CSF) findings showing aseptic inflammation. NBD patients treated with anti-TNFa antibodies for neurological symptoms and specific cerebral parenchymal lesions on magnetic resonance imagery (MRI) were included. Patients with isolated recurrent meningitis or cerebral venous thrombosis without parenchymal NBD lesions were excluded. All patients were refractory and/or intolerant to at least 1 immunosuppressant or high doses of corticosteroids before anti-TNFa initiation. All patients have been treated with immunosuppressants (n ¼ 16) and/or high doses of corticosteroids (n ¼ 17) before anti-TNFa initiation. Immunosuppressive treatments included azathioprine (n ¼ 13, median dosage of 150 mg daily), cyclophosphamide (n ¼ 9), interferon (n ¼ 3), mycophenolate mofetil (n ¼ 2), chlorambucil (n ¼ 2), ciclosporine (n ¼ 1), and methotrexate (n ¼ 1). Patients had received a median of 2 (0; 4) immunosuppressants before anti-TNFa initiation. Corticosteroid pulses were given in 8 patients.
Data Collection and Outcome Measurement
The following data were collected: age, gender, date of BD criteria and of NBD diagnosis, and clinical manifestations of BD (mucocutaneous lesions, eyes, joint, and vascular involvement). The neurological symptoms and the CNS MRI imaging at diagnosis were also reported. The data regarding the therapeutic modalities (drug, dosage, and duration) were collected.
The following terms were used to describe the NBD course: acute form disease course (including single episodes and relapsing-remitting course) or chronic progressive course. To describe the initial status and the outcome under treatment, the Rankin score was used as a marker of disability status. 13 
Study Endpoints
For each patient, we evaluated the clinical and radiological response after anti-TNFa initiation, the time to obtain remission, the occurrence of relapse, and side effects.
Complete remission was defined by the disappearance of all neurological symptoms and by the improvement of radiological abnormalities related to NBD at 12 months after antiTNFa initiation. Partial remission was defined by improvement of neurological symptoms and of radiological abnormalities at 12 months after anti-TNFa initiation and/or by a decrease of more than 50% of the corticosteroids dose as compared with baseline. Other patients were considered as nonresponders.
The relapse was defined by the recurrence of objective neurological symptoms not explained by any other known disease or therapy. The Rankin score was evaluated at the initiation of anti-TNFa and at time of remission.
Statistical Analysis
Continuous variables are presented as median (range or interquartile range as appropriate), and continuous variables before and after anti-TNF were compared between using Wilcoxon rank test. Categorical variables are presented as count (percentage).
RESULTS
Clinical Features
Seventeen BD patients (70.6% of male gender, with a median age of 39. 
Neurological Involvement
Characteristics and outcome of the 17 patients are summarized in Table 1 . All patients had parenchymal NBD, associated with meningitis in 10 patients, optic neuritis in 1, and cerebral thrombophlebitis in 1. Parenchymal lesions involved spinal cord (n ¼ 4), brainstem (n ¼ 8), and/or supra-tentorial
Main symptoms included: switched to tocilizumab with favorable outcome. The median time to achieve remission was 3 (1-6) months (Table 1) . Four patients (23.5%) had a Rankin score 3 at the initiation of anti-TNF therapy. The median Rankin score was 2 (1-4) at the initiation of anti-TNFa versus 1 (0-4) at the time of remission (P ¼ 0.01) (Figure 1 ). After anti-TNF therapy (at last followup), 3 patients (17.6%) had moderate-to-severe disabling sequelae (persistent Rankin score 3; i.e., severe walking deficit). Four patients experienced a relapse of NBD including 2 over anti-TNFa therapy and 2 after cessation of anti-TNFa agents (2 and 12 months after stopping anti-TNFa). Anti-TNFa were stopped because of side effects in 1 and poor compliance to treatment in 1 patient. Radiological abnormalities improved in 73.3% were stable in 20% and worsened in 6.7% of patients. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent (AZA, MTX) ( Table 1) . After a median follow-up of 17.1 (3-163) months, 13 (76.5%) were still receiving anti-TNFa agents. The initial anti-TNFa treatment was discontinued in 5 patients because of side effects (n ¼ 3), treatment failure (n ¼ 1), and relapse (n ¼ 1). 
¼ tumor necrosis factor.
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Corticosteroids Sparing
Doses of corticosteroids decreased significantly at 6 and 12 months after anti-TNFa initiation (median daily dose at baseline of 50 mg vs 15 mg at month 6 [P ¼ 0.004] vs 5 mg at month 12 [P ¼ 0.006]), respectively (Figure 1) . Corticosteroids have been stopped in 4 (23.5%) patients, and reduced by more than 50% as compared with the dosage at baseline in 10 (58.8%) patients. At the end of follow-up the median daily dose of corticosteroids was 6.25 mg.
Side Effects
Side effects occurred in 4 (23.5%) patients (i.e., nausea/ palpitations 
DISCUSSION
In the present study, we report the largest cohort of severe and refractory parenchymal NBD treated by anti-TNFa therapy. To the best of our knowledge, only case reports and small series (i.e., <8 patients) have reported the outcome of NBD patients treated with anti-TNFa. 9 Pipitone et al 9 included 8 NBD patients (3 with new onset NBD), and all patients had partial clinical and radiological improvement after anti-TNFa initiation. A literature review reporting anti-TNFa efficacy in BD has shown a 90% response rate in NBD treated with infliximab. 10 However, these data concerned case reports published in literature, leading to obvious bias (heterogeneous patients and management and selection bias of patients with good response after anti-TNFa treatment). Moreover, accurate data on clinical features and response in NBD patients were not available in this study. Thus data relative to the efficacy of antiTNFa in NBD are lacking. Neurological involvement is 1 of the main causes of disability in BD accounting for 25% of moderate-to-severe disabling sequelae. 5 There is an unmet need for less toxic and more effective immunosuppressive treatments in the management of severe and/or refractory NBD patients. In BD, the efficacy of anti-TNFa has been largely demonstrated mainly in uveitis. 3, 4 Arida et al reported uveitis improvement in 89% and 100% of patients with IFX and ADA, respectively. 10 In an open label, multicenter study of 124 BD patients, intraocular inflammation, macular thickness, and visual acuity, the sparing effect of corticosteroids and immunosuppression load showed a rapid and maintained improvement. Consistently, experts recommend to use anti-TNFa antibodies, as first-line therapy, in BD patients with severe ocular involvement. 4, 14 We have shown that anti-TNFa antibodies may be efficient in severe and refractory NBD patients. Overall improvement following anti-TNFa was evidenced in 94.1% of patients and complete response was achieved in one-third of cases. The onset of action was fast as the median time to achieve remission was of 3 months. The proportion of NBD patients with moderate-to-severe neurological disability could be reduced by 50% and the Rankin score decreased significantly with the use of anti-TNFa therapy. Lastly, anti-TNFa had a significant steroids sparing effect as they can be stopped in 23.5% of patients, and reduced by more than 50% as compared with the dosage at baseline in up to 60% of cases. Taken together, these results are likely to be clinically meaningful. Herein, we included NBD patients with severe neurological involvement as, 41.2% had brainstem lesions, 24% had myelitis, and 58.8% had Rankin score 2 at anti-TNFa initiation. Along this line, the presence of brainstem lesions is an independent risk factor of death and/or persistent Rankin score 3 in NBD. 5 Moreover, our NBD patients had received a median of 2 immunosuppressants before the use of antiTNFa therapy.
The safety profile was acceptable and comparable to that observed in patients with chronic inflammatory arthritis or Crohn disease. Side effects occurred in 23.5% of patients and required treatment discontinuation in 17% of cases.
We acknowledge some limitations in our study. We were unable to collect complete longitudinal data on patients who were seen only on an intermittent basis. Prospective enrollment and data collection from the time of diagnosis would have been ideal but is more difficult to achieve with rare diseases. Small size of patient cohort treated with adalimumab does not allow us to compare them to the infliximab cohort or to make further definitive conclusions. However, anti-TNFa therapy was associated with a beneficial response in 94% of our patients who were resistant to conventional therapies.
Given the unmet needs of these patients, the results presented herein may substantiate future recommendations for their use in refractory NBD.
In conclusion, our results suggest that TNF blockade represents an effective therapeutic approach for patients with severe NBD and resistant to standard immunosuppressive regimens. Further studies are warranted to further evaluate their effectiveness in the management of severe manifestations of BD.
